Patients, AREDS2 Supplements, and Real‑World Adherence

Abstract

AREDS and AREDS2 established that high-dose antioxidant vitamins, zinc, copper, lutein, and zeaxanthin reduce progression to advanced age-related macular degeneration (AMD) in patients with intermediate disease or advanced AMD in one eye.(1–3) A 10‑year follow-up of AREDS2 participants confirmed that the AREDS2 formulation—vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin without β‑carotene—remains effective and safer than the original formula, particularly by avoiding β‑carotene–associated lung cancer risk in former smokers.(2,4,5) Recent re-analyses of AREDS2 imaging data suggest that these supplements may also modestly slow the enlargement of geographic atrophy (GA), especially when atrophy is extrafoveal, though they do not reverse established vision loss.(1,5,6)

Despite robust trial evidence, real‑world adherence to AREDS2-recommended supplementation is suboptimal. Cross-sectional clinic-based studies report that only about 60–67% of eligible AMD patients are taking AREDS2 supplements.(7–9) Among non-users who otherwise meet AREDS criteria, 80–83% state they do not recall being advised about the benefits, indicating that lack of counselling and awareness are dominant barriers, while cost and doubts about efficacy are less frequently cited (~8–10%).(7–9) Interventional work shows that structured education—combining clear verbal and written instructions and repeated reinforcement across visits—can raise adherence from roughly 44% to over 80%.(10) This article summarizes the evidence for AREDS2 efficacy, synthesizes data on adherence patterns and barriers, and outlines practical, patient-centred strategies to improve long-term adherence to eye vitamin regimens.

AREDS2 Efficacy and What Patients Are Told

AREDS2 confirmed that, in patients with intermediate AMD or advanced AMD in one eye, a daily formulation of vitamin C 500 mg, vitamin E 400 IU, zinc (commonly 80 mg as zinc oxide), copper 2 mg, lutein 10 mg, and zeaxanthin 2 mg reduces the risk of progression to late AMD.(2,3,4) Analyses of the 10‑year follow-up demonstrate sustained benefit and show that replacing β‑carotene with lutein/zeaxanthin slightly improves efficacy while substantially reducing lung cancer risk in former smokers.(2,4,5) A recent secondary analysis found that AREDS2 supplements also appear to modestly slow GA growth, particularly when the atrophic area is non-foveal, although they do not restore lost central vision.(1,5,6)

Patient-facing materials from national organizations emphasize key messages: supplements are indicated only for specific AMD stages, they slow but do not cure AMD, and they are intended to complement—not replace—dietary and lifestyle measures such as smoking cessation and a carotenoid-rich diet.(1,4,6) Clear communication of these nuances is critical to set realistic expectations and support adherence.

Real‑World Adherence to AREDS2 Eye Vitamins

Observed Adherence Rates

Several clinic-based studies have evaluated how many patients who meet AREDS criteria actually take AREDS2 supplements:

• A retrospective telephone-based study in a tertiary clinic (70 eligible patients) reported that about two‑thirds of patients were taking AREDS2 vitamins.(7)
• A larger series of 120 patients meeting AREDS criteria found that 60% were taking AREDS2 supplements, while 40% were not.(8,9)
• A prospective survey comparing two clinics—one with structured education and one without—found adherence rates of 81.6% versus 44.1%, respectively, underscoring the impact of systematic counselling.(10)

Overall, these data suggest that in routine practice only 60–70% of eligible AMD patients are adherent to AREDS2 supplementation, substantially below the potential uptake implied by trial participation.(7–10)

Key Barriers Identified

Across studies, the dominant barrier to AREDS2 use is not cost or side effects but lack of awareness:

• In the 120‑patient series, among those not taking AREDS2, 83% reported they did not recall ever being advised about supplement benefits.(8,9)
• In the 70‑patient cohort, 88% of eligible non-users similarly reported no recollection of being told to take AREDS2 vitamins.(7)

Other reported barriers include:

• Cost: cited by about 8–10% of non-adherent patients.(7–9)
• Perceived lack of benefit: only a small minority (4–10%) explicitly stated they did not believe supplements would help.(7–9)
• General adherence factors: broader literature on chronic medication use highlights low motivation, competing health priorities, pill burden, and cognitive issues as contributors to non-adherence, which likely apply to eye vitamins as well.(10,11)

Importantly, the presence of clear, repeated recommendations from the treating ophthalmologist is strongly associated with higher adherence.(7–10)

Drivers of Adherence: What Works

Education and Communication

Multiple data sources converge on the importance of the clinician–patient relationship and education:

• In anti‑VEGF–treated AMD and diabetic macular edema, qualitative interviews show that the doctor–patient relationship and quality of counselling are the top drivers of adherence to intravitreal treatments.(12)
• For AREDS2 vitamins specifically, structured educational policies—providing verbal and written explanations, repeating instructions at each visit, and involving multiple team members—have been associated with adherence rates above 80%, compared with about 44% without such protocols.(10)

Effective educational strategies include:

• Explaining the goal (slowing progression, not curing disease or restoring lost vision).
• Clarifying who benefits (intermediate AMD/advanced in one eye) and why someone with very early or very advanced disease may derive less benefit.(1,2,4,6)
• Discussing safety, especially the rationale for avoiding β‑carotene in current and former smokers.(2,4,5)
• Providing written instructions and product examples to reduce confusion in the pharmacy or online marketplace.(4,7–10)

Practical Support and Simplification

Adherence improves when patients can easily incorporate eye vitamins into daily routines. Suggested approaches include:

• Aligning dosing with existing daily habits (for example with breakfast or evening medications).
• Recommending once-daily formulations rather than multiple daily doses where possible.(4,7–10)
• Encouraging use of pill organizers or smartphone reminders, particularly in older adults with polypharmacy.(10,11)

Where cost is a barrier, clinicians can discuss generic or store-brand AREDS2-equivalent options and clarify that multivitamins alone are not sufficient substitutes for AREDS2-level dosing.(1,4,6,8,9)

Translating Evidence into Patient-Centred Practice

From a practical standpoint, improving AREDS2 adherence in clinic populations likely requires:

• Proactive identification of patients who meet AREDS criteria (intermediate AMD, or advanced in one eye).
• Standardized counselling protocols embedded in clinic workflows, ensuring that all eligible patients receive consistent messages from multiple team members and written reinforcement.(7–10)
• Documentation of supplement recommendations in the chart so future visits can revisit and reinforce the message.
• Follow-up questions (“Are you still taking your AREDS2 vitamins?” “Any problems with cost or side effects?”) to detect lapses early and troubleshoot barriers.

Real‑world data suggest that when patients clearly understand the rationale, see their clinicians emphasizing supplements as part of a comprehensive plan, and receive practical help integrating them into daily life, adherence can approach or exceed 80%.(7–10)

Conclusion

AREDS2 eye vitamin supplements have a well-established role in reducing progression to advanced age-related macular degeneration in appropriately selected patients, with long-term follow-up confirming durable benefit and improved safety compared with the original β‑carotene–containing formula.(1–5) Emerging analyses suggest they may modestly slow geographic atrophy extension, particularly in extrafoveal lesions, while not restoring lost central vision.(1,5,6)

In routine practice, however, only about 60–70% of eligible patients report taking AREDS2 supplements, and most non-users simply do not recall being advised rather than actively rejecting treatment or being unable to afford it.(7–9) Structured, repetitive education and strong clinician–patient communication markedly improve adherence and should be integrated into AMD care pathways. By pairing clear, evidence-based messages with practical support, clinicians can help more patients realize the potential benefits of AREDS2 supplementation as part of a broader strategy that also includes lifestyle modification, regular monitoring, and, when indicated, pharmacologic therapies.

This article is for educational purposes only and reflects current scientific literature at the time of writing.

References

1. BrightFocus Foundation. New study confirms the efficacy of AREDS2 eye vitamin supplement for slowing age-related macular degeneration. 2025. https://www.brightfocus.org/resource/new-study-confirms-the-efficacy-of-areds2-eye-vitamin-supplement-for-slowing-age-related-macular-degeneration[brightfocus] 
2. Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega‑3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005–2015. https://jamanetwork.com/journals/jama/fullarticle/1684847[jamanetwork] 
3. National Eye Institute. Age-Related Eye Disease Studies (AREDS/AREDS2). 2025. https://www.nei.nih.gov/eye-health-information/clinical-trials/age-related-eye-disease-studies-aredsareds2[nei.nih] 
4. BrightFocus Foundation. Explaining the results from the AREDS2 study. 2025. https://www.brightfocus.org/resource/explaining-the-results-from-the-areds2-study[brightfocus] 
5. Chew EY, Clemons TE, Agrón E, et al. Long-term outcomes of adding lutein/zeaxanthin and ω‑3 fatty acids to the AREDS supplements on AMD progression and lung cancer: AREDS2 10‑year follow-up. JAMA Ophthalmol. 2022;140(8):834–843. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2792855[jamanetwork] 
6. Macular Society. AREDS2 supplements slow sight loss in late-stage dry AMD. 2024. https://www.macularsociety.org/about/media/news/2024/july/areds2-supplements-slow-sight-loss-in-late-stage-dry-amd[macularsociety] 
7. Euretina Abstract. Adherence of patients with age-related macular degeneration to AREDS2-recommended vitamin supplements. 2022. https://euretina.org/resource/abstract_2022_adherence-of-patients-with-age-related-macular-degeneration-to-areds-2-recommended-v[euretina] 
8. Alghamdi A, et al. Adherence of patients with age-related macular degeneration to AREDS2-recommended nutritional supplements. Ophthalmic Res. 2023;xx:xx–xx. Summary at PubMed. https://pubmed.ncbi.nlm.nih.gov/36971785/[pubmed.ncbi.nlm.nih] 
9. Retina Associates / Mater Misericordiae University Hospital. Adherence of patients with age-related macular degeneration to AREDS2-recommended nutritional supplements. 2023. https://retinaassociates.ie/adherence-of-patients-with-age-related-macular-degeneration-to-areds-2-recommended-nutritional-suppl[retinaassociates] 
10. Optometry Times. Adherence and persistence: when patients take their health into their own hands. 2023. https://www.optometrytimes.com/view/adherence-and-persistence-when-patients-take-their-health-into-their-own-hands[optometrytimes] 
11. Bosworth HB, Granger BB, Mendys P, et al. Medication adherence: a call for action. Am Heart J. 2011;162(3):412–424. Summarized in Optometry Times article.[optometrytimes] 
12. Finger RP, Wiedemann P, Blum M, et al. Drivers of and barriers to adherence to neovascular AMD and DME treatment: qualitative interviews with patients, caregivers, and retina specialists. Clin Ophthalmol. 2022;16:775–789. https://pmc.ncbi.nlm.nih.gov/articles/PMC8901255/[pmc.ncbi.nlm.nih]